Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 017.5 JPY -2.23% Market Closed
Market Cap: 2.3T JPY

Olympus Corp
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Olympus Corp
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Olympus Corp
TSE:7733
Cash from Operating Activities
Â¥152B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
9%
Paramount Bed Holdings Co Ltd
TSE:7817
Cash from Operating Activities
Â¥10B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
2%
Terumo Corp
TSE:4543
Cash from Operating Activities
Â¥211.9B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
10%
Sysmex Corp
TSE:6869
Cash from Operating Activities
Â¥76.2B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
7%
Nihon Kohden Corp
TSE:6849
Cash from Operating Activities
Â¥21.7B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
6%
JEOL Ltd
TSE:6951
Cash from Operating Activities
Â¥23.1B
CAGR 3-Years
2%
CAGR 5-Years
42%
CAGR 10-Years
9%
No Stocks Found

Olympus Corp
Glance View

Market Cap
2.3T JPY
Industry
Health Care

Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes. Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.

Intrinsic Value
2 290.08 JPY
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Olympus Corp's Cash from Operating Activities?
Cash from Operating Activities
152B JPY

Based on the financial report for Jun 30, 2025, Olympus Corp's Cash from Operating Activities amounts to 152B JPY.

What is Olympus Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
9%

Over the last year, the Cash from Operating Activities growth was 28%. The average annual Cash from Operating Activities growth rates for Olympus Corp have been 8% over the past three years , 6% over the past five years , and 9% over the past ten years .

Back to Top